Results 21 to 30 of about 5,257 (166)

Analysis of the usefulness and benefits of ultrafiltration in cardiorenal syndrome: A systematic review

ESC Heart Failure, Volume 12, Issue 2, Page 1194-1202, April 2025.
Abstract Aims Cardiac decompensation in cardiorenal syndrome (CRS) results in systemic congestion usually treated with diuretics. When despite high doses of diuretics, response is poor, ultrafiltration (UF) appears to be a useful and safe technique.
Borja Guerrero Cervera, Raquel López‐Vilella, Víctor Donoso Trenado, María Peris‐Fernández, Paula Carmona, Amparo Soldevila, Sergi Tormo, Ramón Devesa, María Jesús Montero Hernández, Luis Martínez Dolz, Julio Hernández Jaras, Pilar Sánchez‐Pérez, Luis Almenar‐Bonet   +12 more
wiley   +1 more source

Plasma volume status predicting clinical outcomes in patients undergoing transcatheter edge‐to‐edge mitral valve repair

ESC Heart Failure, EarlyView.
Abstract Aims Plasma volume status (PVS) is recognized as a marker of systemic congestion, but its clinical utility in patients with mitral regurgitation (MR) undergoing transcatheter edge‐to‐edge mitral valve repair (M‐TEER) has not been well established. This study aimed to evaluate the prognostic significance of PVS in these patients.
Ai Kagase, Masanori Yamamoto, Takahiro Tokuda, Ryotaku Kawahata, Hiroto Nishio, Tetsuro Shimura, Ryo Yamaguchi, Mitsuru Sago, Yuki Izumi, Mike Saji, Masahiko Asami, Yusuke Enta, Masaki Nakashima, Shinichi Shirai, Masaki Izumo, Shingo Mizuno, Yusuke Watanabe, Makoto Amaki, Kazuhisa Kodama, Junichi Yamaguchi, Toru Naganuma, Hiroki Bouta, Yohei Ohno, Masahiro Yamawaki, Hiroshi Ueno, Kazuki Mizutani, Daisuke Hachinohe, Toshiaki Otsuka, Shunsuke Kubo, Kentaro Hayashida, OCEAN‐Mitral Investigators   +30 more
wiley   +1 more source

Dapagliflozin effect on functional mitral regurgitation and myocardial remodelling: The DEFORM trial

ESC Heart Failure, EarlyView.
Abstract Aims Functional mitral regurgitation (FMR) is associated with adverse outcomes in patients with heart failure, and current guideline‐directed medical therapy (GDMT) offers limited efficacy in managing FMR. This study aims to evaluate the therapeutic impact of the sodium‐glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in patients with ...
Zhuoshan Huang, Rui Fan, Shaozhao Zhang, Junlin Zhong, Yiquan Huang, Peihan Xie, Shanshan Yin, Xiaomin Ye, Xinghao Xu, Rihua Huang, Zhenyu Xiong, Yue Guo, Menghui Liu, Yifen Lin, Suhua Li, Xiaoxian Qian, Jinlai Liu, Xiaodong Zhuang, Xinxue Liao   +18 more
wiley   +1 more source

Autosomal Dominant Polycystic Kidney Disease Patients Requiring Nephrectomy: Characteristics and Surgical Considerations

ANZ Journal of Surgery, EarlyView.
ABSTRACT Background Nephrectomies are major surgeries often required in ADPKD for symptom control, removal of septic/malignant foci, and to create space for renal transplantation. Whether ADPKD patients should proceed with nephrectomy/ies should be guided by patient characteristics, technical considerations and anticipated risks and benefits. Methods A
Joel Ern Zher Chan, Kate S. Olakkengil, Shantanu Bhattacharjya, Santosh Antony Olakkengil   +3 more
wiley   +1 more source

Developments in albuminuria testing: A key biomarker for detection, prognosis and surveillance of kidney and cardiovascular disease—A practical update for clinicians

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Albuminuria, the abnormal presence of albumin in urine, is a key marker of kidney damage and a strong predictor of kidney and cardiovascular outcomes. Its clinical significance has evolved from early historical observations to its current role in chronic kidney disease (CKD) detection, risk stratification and treatment monitoring.
Jelle M. Beernink, Dominique van Mil, Gozewijn D. Laverman, Hiddo J. L. Heerspink, Ron T. Gansevoort   +4 more
wiley   +1 more source

A Dose‐Tailored Anti‐Plasma Cell Regimen Lowers the Mortality of Late‐Stage Cardiac Amyloidosis

MedComm, Volume 6, Issue 7, July 2025.
The present study was designed to assess the efficacy and safety of a dose‐tailored BD regimen and a dose‐tailored DBD regimen in patients with LCCA at Mayo Stage III. Both the two regimens markedly increased survival rate and time in those patients and the dose‐tailored DBD regimen was superior to the dose‐tailored BD regimen in both efficacy and ...
Yun Ti, Huaitao Yu, Ying Wang, Mei Ni, Tongtao Liu, Luqun Wang, Cheng Zhang, Peili Bu, Yun Zhang   +8 more
wiley   +1 more source

Tolvaptan as a tool in renal physiology

American Journal of Physiology-Renal Physiology, 2014
For decades, the Brattleboro rat has been a useful model in kidney physiology. These animals manifest central diabetes insipidus (lack of circulating vasopressin) due to a mutation in the vasopressin-neurophysin gene. V2 receptor-mediated vasopressin actions in the kidney can be assessed in these animals by infusing the V2-selective vasopressin analog ...
Chung-Lin Chou, Mark A. Knepper, Carlos A. Miranda, Jae Wook Lee   +3 more
openaire   +4 more sources

Clinical evaluation and outcome in heart failure patients receiving chemotherapy with different anti‐cancer agents

ESC Heart Failure, Volume 12, Issue 3, Page 1965-1976, June 2025.
Abstract Background The optimal strategy for modern chemotherapy should be based on a comprehensive approach for cancer patients with cardiovascular diseases. Therefore, cardio‐oncology has received increasing attention owing to the cardiotoxic effects of anti‐cancer therapies.
Tomiko Sunaga, Takahiro Okada, Yoshitaka Iso, Mio Ebato, Tsutomu Toshida, Shuichi Nawata, Hiroshi Suzuki, Mari Kogo   +7 more
wiley   +1 more source

Randomized trial to assess worsening renal function by adding dapagliflozin for acute decompensated heart failure

ESC Heart Failure, Volume 12, Issue 3, Page 2023-2033, June 2025.
Abstract Aims Dapagliflozin (DAPA), a sodium‐glucose co‐transporter 2 inhibitor, has been shown to reduce cardiovascular mortality among patients with chronic heart failure. We aimed to evaluate the impact on a worsening renal function (WRF) by adding DAPA as compared to standard decongestive therapy with loop diuretics alone.
Shodai Kawanami, Yasuyuki Egami, Masaru Abe, Mizuki Osuga, Hiroaki Nohara, Kohei Ukita, Akito Kawamura, Koji Yasumoto, Naotaka Okamoto, Yasuharu Matsunaga‐Lee, Masamichi Yano, Masami Nishino   +11 more
wiley   +1 more source

Review of Tolvaptan in the Treatment of Hyponatremia [PDF]

Clinical Medicine Insights: Therapeutics, 2011
Hyponatremia is a very common electrolyte disorder and is a significant independent predictor of medical prognosis and costs. Tolvaptan is a vasopressin receptor antagonist developed for the treatment of hyponatremia. It has its principal application in the treatment of euvolemic and hypervolemic hyponatremia.
Apurv Khanna, Amarinder Singh Garcha
openaire   +2 more sources